Fanconi Anemia (Hematological Disorders) Pipeline Forecast Report – Pharmaceutical Disease Pipeline Guide, H1, 2017

Albany, New York, June 2, 2017:  Market Research Hub’s Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1107560
Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconis anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn’t make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body’s organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/L.
The Fanconi Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 3 molecules, respectively.

Fanconi Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope:

– The pipeline guide provides a snapshot of the global therapeutic landscape of Fanconi Anemia (Hematological Disorders).
– The pipeline guide reviews pipeline therapeutics for Fanconi Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Fanconi Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Fanconi Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Fanconi Anemia (Hematological Disorders)

Browse Full Report with TOC @ http://www.marketresearchhub.com/report/fanconi-anemia-pipeline-review-h1-2017-report.html

Reasons to Buy:

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Fanconi Anemia (Hematological Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Fanconi Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents:
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fanconi Anemia – Overview
Fanconi Anemia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fanconi Anemia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fanconi Anemia – Companies Involved in Therapeutics Development
Abeona Therapeutics Inc
Genethon SA
Fanconi Anemia – Drug Profiles
ABO-301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-6626 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy to Activate FANC-A for Fanconi Anemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP4-039 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fanconi Anemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Fanconi Anemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate FANCA Protein for Fanconi Anemia – Drug Profile

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 866-997-4948 (US-Canada)

Tel: +1-518-621-2074

Email: press@marketresearchhub.com

Read More Industry News @ https://www.industrynewsanalysis.com/

Related Posts Plugin for WordPress, Blogger...